



FORM PTO-1449 (Rev. 10-2002) and B (modified PTO/SB/08)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	I	of	8
-------	---	----	---

APPLICATION NO.: 10/743,625	ATTY. DOCKET NO.: C1039.70073US00
FILING DATE: December 22, 2003	CONFIRMATION NO.: 9416
APPLICANT: Arthur M. Krieg et al.	
GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		5,284,656		Platz et al.	02-08-1994
		5,451,569		Wong et al.	09-19-1995
		5,780,448		Davis	07-14-1998
		5,804,566		Carson et al.	09-08-1998
		5,830,877		Carson et al.	11-03-1998
		5,985,847		Carson et al.	11-16-1999
		6,086,898		DeKruyff et al.	07-11-2000
		6,225,292	B1	Raz et al.	05-01-2001
		6,558,670	B1	Friede et al.	05-06-2003
		6,610,308	B1	Haensler	08-26-2003
		6,787,524	B2	Chang et al.	09-07-2004
		6,994,870	B2	Tsai	02-07-2006
		7,034,007	B1	Nyce et al.	04-25-2006
		7,208,478	B2	Carson et al.	04-24-2007
		7,223,398	B1	Tuck et al.	05-29-2007
		7,306,782	B2	Borel et al.	12-11-2007
		7,354,711	B2	Macfarlane	04-08-2008
		7,410,975	B2	Lipford et al.	08-12-2008
		7,514,414	B2	Klinman et al.	04-07-2009
		7,514,415	B2	Klinman et al.	04-07-2009
		7,534,772	B2	Weiner et al.	05-19-2009
		7,566,703	B2	Krieg et al.	07-28-2009
		7,569,553	B2	Kreig	08-04-2009
		7,576,066	B2	Krieg	08-18-2009
		7,585,847	B2	Bratzler et al.	09-08-2009
		7,605,138	B2	Krieg	10-20-2009
		7,615,539	B2	Krieg et al.	11-10-2009
		7,674,777	B2	Krieg	03-09-2010
		2002-0102255	A1	Chang	08-01-2002
		2004-0038922	A1	Haensler et al.	02-26-2004

EXAMINER: /N. M. Minnifield/ (08/01/2010)	DATE CONSIDERED:
--	------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/818,918, filed March 27, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	2	of	8
-------	---	----	---

APPLICATION NO.: 10/743,625

ATTY. DOCKET NO.: C1039.70073US00

FILING DATE: December 22, 2003

CONFIRMATION NO.: 9416

APPLICANT: Arthur M. Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: Nita M. Minnifield

		2004-0064064	A1	Zhou et al.	04-01-2004
		2004-0247662	A1	Dow et al.	12-09-2004
		2004-0248837	A1	Raz et al.	12-09-2004
		2005-0031638	A1	Dalemans et al.	02-10-2005
		2005-0209183	A1	Kippenberger et al.	09-22-2005
		2005-0261215	A1	Garren et al.	11-24-2005
		2006-0002959	A1	Glenn et al.	01-05-2006
		2006-0002962	A1	Jacobi et al.	01-05-2006
		2006-0171968	A1	Brimnes et al.	08-03-2006
		2007-0243209	A1	Segal et al.	10-18-2007
		2008-0009455	A1	Krieg et al.	01-10-2008
		2008-0026011	A1	Krieg et al.	01-31-2008
		2008-0031936	A1	Krieg et al.	02-07-2008
		2008-0045473	A1	Uhlmann et al.	02-21-2008
		2008-0113929	A1	Lipford et al.	05-15-2008
		2008-0226649	A1	Schetter et al.	09-18-2008
		2008-0260751	A1	Karp et al.	10-23-2008
		2009-0017021	A1	Davis et al.	01-15-2009
		2009-0060927	A1	Wagner et al.	03-05-2009
		2009-0117132	A1	Readett et al.	05-07-2009
		2009-0137519	A1	Krieg et al.	05-28-2009
		2009-0142362	A1	Krieg et al.	06-04-2009
		2009-0155212	A1	Bratzler et al.	06-18-2009
		2009-0155307	A1	Davis et al.	06-18-2009
		2009-0191188	A1	Krieg et al.	07-30-2009
		2009-0202575	A1	Krieg et al.	08-13-2009
		2009-0214578	A1	Bauer	08-27-2009
		2009-0306177	A1	Uhlmann et al.	12-10-2009
		2009-0311277	A1	Krieg	12-17-2009

EXAMINER:

/N. M. Minnifield/ (08/01/2010)

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/818,918, filed March 27, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/743,625	ATTY. DOCKET NO.: C1039.70073US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: December 22, 2003	CONFIRMATION NO.: 9416
				APPLICANT: Arthur M. Krieg et al.	
				GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield
Sheet	3	of	8		

FOREIGN PATENT DOCUMENTS

Examiner's Initials [#]	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		EP	1 671 646	A2	Dynavax Tech Corp	06-21-2006	
	*	WO	98/18810	A1	University of Iowa Research Foundation	05-07-1998	
	*	WO	98/40100	A1	Ottawa Civic Loeb Research Institute	09-17-1998	
	*	WO	98/52581	A1	Ottawa Civic Hospital Loeb Research Inst.	11-26-1998	
		WO	00/15256	A2	Pasteur Merieux Serums Et Vaccins [FR]	03-23-2000	Y-Abstract Only
		WO	00/20039	A1	The Regents of the University of California	04-13-2000	
		WO	00/61151	A2	The Government of the United States of America	10-19-2000	
		WO	01/35991	A2	Dynavax Technologies Corporation	05-25-2001	
		WO	02/28428	A2	Aventis Pasteur [FR]	04-11-2002	Y-Abstract Only
		WO	03/043572	A2	3M Innovative Properties Company	05-30-2003	
		WO	2004/041183	A2	The Regents of the University of California	05-21-2004	
		WO	2006/091591	A1	The Regents of the University of California	08-31-2006	
		WO	2006/096497	A2	Dynavax Technologies Corporation	09-14-2006	
		WO	2007/095316	A2	Coley Pharmaceutical GmbH	08-23-2007	
		WO	2008/030455	A2	Coley Pharmaceutical Group, Inc.	03-13-2008	
		WO	2008/033432	A2	Coley Pharmaceutical Group, Inc.	03-20-2008	
		WO	2008/039538	A2	Coley Pharmaceutical Group, Inc.	04-03-2008	
		WO	2008/068638	A2	Coley Pharmaceutical GMBH	06-12-2008	
		WO	2008/139262	A2	Coley Pharmaceutical GMBH	11-20-2008	

EXAMINER: /N. M. Minnifield/ (08/01/2010)	DATE CONSIDERED:
--	------------------

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/818,918, filed March 27, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	4	of	8
-------	---	----	---

APPLICATION NO.: 10/743,625	ATTY. DOCKET NO.: C1039.70073US00
FILING DATE: December 22, 2003	CONFIRMATION NO.: 9416
APPLICANT: Arthur M. Krieg et al.	
GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials [#]	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		[NO AUTHOR LISTED] CpG oligonucleotide adjuvants modulate allergic response in mouse model. Allergy Medicine, NewsRx.com. January 16, 2000. (Jahnschmid)	
		[NO AUTHOR LISTED] Cytos Biotechnology AG, "Cytos Biotechnology updates on development of allergy vaccine", Press Release. 2006;4 pages.	
		ARORA et al., Immunomodulation by liposome entrapped allergen. Mol Cell Biochem. 1990 Sep 21;97(2):173-9. Abstract Only.	
		CELLA et al., Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol. 2000 Oct;1(4):305-10.	
		CELLA et al., Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999 Aug;5(8):919-23.	
		CHO et al., Immunostimulatory DNA inhibits transforming growth factor-beta expression and airway remodeling. Am J Respir Cell Mol Biol. 2004 May;30(5):651-61. Epub 2003 Nov 14.	
		COOPER et al., Safety and immunogenicity of CPG 7909 injection as an adjuvant to FluArix influenza vaccine. Vaccine. 2004 Aug 13;22(23-24):3136-43.	
		CRETICOS et al., Immunotherapy with immunostimulatory oligonucleotides linked to purified ragweed Amb a 1 allergen: effects on antibody production, nasal allergen provocation, and ragweed seasonal rhinitis. J Allergy Clin Immunol. 2002;109(4):743-44. Abstract #3.	
		ERB et al., Novel vaccines protecting against the development of allergic disorders: a double-edged sword? Curr Opin in Immunol. 2002;14:633-43.	
		FANUCCHI et al., Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys. Am J Respir Crit Care Med. 2004 Dec 1;170(11):1153-7. Epub 2004 Aug 11.	
		FARKAS et al., Plasmacytoid dendritic cells activate allergen-specific TH2 memory cells: modulation by CpG oligodeoxynucleotides. J Allergy Clin Immunol. 2004 Aug;114(2):436-43.	
		FERREIRA et al., Customized antigens for desensitizing allergic patients. Adv Immunol. 2004;84:79-129. Abstract Only.	
		FORNADLEY, Allergy immunotherapy. Otolaryngol Clin North Am. 1998 Feb;31(1):111-27. Abstract Only.	
		GAUVREAU et al., Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am J Respir Crit Care Med. 2006 Jul 1;174(1):15-20. Epub 2006 Mar 30.	
		GAVETT et al., Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med. 1995 Nov 1;182(5):1527-36.	
		GOLDBERG et al., Beyond danger: unmethylated CpG dinucleotides and the immunopathogenesis of disease. Immunol Lett. 2000 Jul 3;73(1):13-8.	
		HALLSWORTH et al., Selective enhancement of GM-CSF, TNF-alpha, IL-1 beta and IL-8 production by monocytes and macrophages of asthmatic subjects. Eur Respir J. 1994 Jun;7(6):1096-102.	
		HALPERIN et al., A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide	

EXAMINER:

/N. M. Minnifield/ (08/01/2010)

DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/818,918, filed March 27, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	5	of	8
-------	---	----	---

APPLICATION NO.: 10/743,625	ATTY. DOCKET NO.: C1039.70073US00
FILING DATE: December 22, 2003	CONFIRMATION NO.: 9416
APPLICANT: Arthur M. Krieg et al.	
GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

adjuvant. Vaccine. 2003 Jun 2;21(19-20):2461-7.

HANCOCK et al., CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV). Vaccine. 2001 Sep 14;19(32):4874-82.

HAWKES et al., Times of London News International. 4M:18. Printed on September 18, 1999.

HAYASHI et al., TLR9-based immunotherapy for allergic disease. Am J Med. 2006 Oct;119(10):897.e1-6.

HESSEL et al., Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction. J Exp Med. 2005 Dec 5;202(11):1563-73.

HIGAKI et al., Cell death and survival in response to immunostimulatory sequence oligodeoxynucleotides treatment in a murine model of allergic asthma. J Allergy Clin. Immunol. 2006 Feb;S156. Abstract #607.

HOFFJAN et al., Toll-like receptors and airway disease. Drug Discov Today. 2006;3(3):317-24

HUSSAIN et al., Modulation of murine allergic rhinosinusitis by CpG oligodeoxynucleotides. Laryngoscope. 2002 Oct;112(10):1819-26.

ILIEV et al., Immunostimulatory oligodeoxynucleotide containing TTTCTGTTT motif from Lactobacillus rhamnosus GG DNA potentially suppresses OVA-specific IgE production in mice. Scand J Immunol. 2008 Apr;67(4):370-6. Epub 2008 Feb 1.

KAY et al., Allergy and allergic diseases. Second of two parts. N Engl J Med. 2001 Jan 11;344(2):109-13.

KIM et al., TLR9 agonist immunomodulator treatment of cutaneous T-cell lymphomas (CTCL) with CPG7909. Blood. 2004 Nov 16;104(11):Abstract #743.

KIPS et al., Interleukin-12 inhibits antigen-induced airway hyperresponsiveness in mice. Am J Respir Crit Care Med. 1996 Feb;153(2):535-9.

KITAGAKI et al., Oral administration of CpG-ODNs suppresses antigen-induced asthma in mice. Clin Exp Immunol. 2006 Feb;143(2):249-59.

KLINE, Eat dirt: CpG DNA and immunomodulation of asthma. Proc Am Thorac Soc. 2007 Jul;4(3):283-8. Review.

KLINE, Immunotherapy of asthma using CpG oligodeoxynucleotides. Immunol Res. 2007;39(1-3):279-86. Review.

KLINE et al., Ch. 26: DNA Immunomodulation of asthma. In Inflammatory Mechanisms in Allergic Diseases. Ed., Zeiman et al. Marcel Dekker, Inc. 2002;551-64.

KLINE et al., Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect. 2008 Oct;21(8):434-9.

KLINMAN et al., Synthetic oligonucleotides as modulators of inflammation. J Leukoc Biol. 2008 Oct;84(4):1-7. Epub 2008 Apr 22.

KOU et al., [Analysis and regulation of interferon-gamma production by peripheral blood lymphocytes from patients with bronchial asthma] Arerugi. 1994 Mar;43(3):482-91. Japanese. Y-Abstract Only

KRIEG, Now I know my CpGs. Trends Microbiol. 2001 Jun;9(6):249-52.

EXAMINER:

/N. M. Minnifield/ (08/01/2010)

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/818,918, filed March 27, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/743,625	ATTY. DOCKET NO.: C1039.70073US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: December 22, 2003	CONFIRMATION NO.: 9416
				APPLICANT: Arthur M. Krieg et al.	
				GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield
Sheet	6	of	8		

		KRUG et al., Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001 Oct;31(10):3026-37.	
	*	KUSSEBI et al., Advances in immunological treatment of allergy. Curr Med Chem. 2003;2:297-308.	
		LEATH et al., Novel and emerging therapies for asthma. Drug Discov Today. 2005 Dec;10(23-24):1647-55.	
		LEE et al., Immunostimulatory DNA inhibits allergen-induced peribronchial angiogenesis in mice. J Allergy Clin Immunol. 2006 Mar;117(3):597-603. Epub 2006 Jan 27.	
	*	LEUNG et al., Pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 1999 Sep;104(3 Pt 2):S99-108.	
		LIU et al., CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat Immunol. 2003 Jul;4(7):687-93. Epub 2003 May 25.	
		MACAUBAS et al., Respiratory tolerance in the protection against asthma. Curr Drug Targets Inflamm Allergy. 2003 Jun;2(2):175-86.	
		MARSHALL et al., Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol. 2001 Aug;108(2):191-7.	
		MARTIN et al., Immunotherapy as a disease modifier. Paediatr Respir Rev. 2006;7 Suppl 1:S106-7. Epub 2006 Jun 5.	
		MILGROM et al., Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med. 1999 Dec 23;341(26):1966-73. Abstract Only.	
		MURAD et al., CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol Ther. 2007 Aug;7(8):1257-66. Abstract Only.	
		MUTWIRI et al., Biological activity of immunostimulatory CpG DNA motifs in domestic animals. Vet Immunol Immunopathol. 2003 Jan 30;91(2):89-103.	
		NELSON, Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol. 2007 Apr;119(4):872-80. Epub 2007 Feb 9. Abstract Only.	
		NELSON, Allergen immunotherapy: where is it now? J Allergy Clin Immunol. 2007 Apr;119(4):769-79. Epub 2007 Mar 2. Abstract Only.	
		NYCE, Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases. Expert Opin Investig Drugs. 1997 Sep;6(9):1149-56.	
		PENG et al., CpG oligodeoxynucleotide vaccination suppresses IgE induction but may fail to down-regulate ongoing IgE responses in mice. Int Immunol. 2001 Jan;13(1):3-11.	
	*	RAZ et al., Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A. 1996 May 14;93(10):5141-5.	
		RHEE et al., Allergen-independent immunostimulatory sequence oligodeoxynucleotide therapy attenuates experimental allergic rhinitis. Immunology. 2004 Sep;113(1):106-13.	
		SAITO et al., Allergen-induced murine upper airway inflammation: local and systemic changes in murine experimental allergic rhinitis. Immunology. 2001 Oct;104(2):226-34.	
		SIMONS et al., Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol. 2004 Jun;113(6):1144-51.	
EXAMINER:		DATE CONSIDERED:	
/N. M. Minnifield/ (08/01/2010)			

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/818,918, filed March 27, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	7	of	8
-------	---	----	---

APPLICATION NO.: 10/743,625	ATTY. DOCKET NO.: C1039.70073US00
FILING DATE: December 22, 2003	CONFIRMATION NO.: 9416
APPLICANT: Arthur M. Krieg et al.	
GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

- | | | |
|--|---|---|
| | SMIT et al., Therapeutic treatment with heat-killed <i>mycobacterium vaccae</i> (SRL172) in a mild and severe mouse model for allergic asthma, Eur. J. of Pharm., 2003; 470:193-9. | |
| | SPEISER et al., Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005 Mar;115(3):739-46. | |
| | SPIEGELBERG et al., Allergen-immunostimulatory oligodeoxynucleotide conjugate: a novel allergoid for immunotherapy. Curr Opin Allergy Clin Immunol. 2002 Dec;2(6):547-51. Abstract Only. | |
| | STRIETER, What differentiates normal lung repair and fibrosis? Inflammation, resolution of repair, and fibrosis. Proc Am Thorac Soc. 2008 Apr 15;5(3):305-10. | |
| | TAUBE et al., Insights into the pathogenesis of asthma utilizing murine models. Int Arch Allergy Immunol. 2004 Oct;135(2):173-86. | |
| | TAYYARI et al., CpG-oligodeoxynucleotides inhibit RSV-enhanced allergic sensitisation in guinea pigs. Eur Respir J. 2005 Feb;25(2):295-302. | |
| | THORNE et al., Experimental grain dust atmospheres generated by wet and dry aerosolization techniques. Am J Ind Med. 1994 Jan;25(1):109-12. Abstract Only. | |
| | TIGHE et al., Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol. 2000 Jul;30(7):1939-47. | |
| | VAN OJIK et al., Phase I/II study with CpG 7909 as adjuvant to vaccination with MAGE-3 protein in patients with MAGE-3 positive tumors. Ann Oncol. 2003;13:157. Abstract 5790. | |
| | VOLLMER, TLR9 in health and disease. Int Rev Immunol. 2006 May-Aug;25(3-4):155-81. | |
| | WEERATNA et al., Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. 1998 Aug;8(4):351-6. | |
| | WEINER et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10833-7. | |
| | WEISS et al., Design of protective and therapeutic DNA vaccines for the treatment of allergic diseases. Curr Drug Targets Inflamm Allergy. 2005 Oct;4(5):585-97. | |
| | YAMAMOTO et al., [Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of action of oligonucleotide fraction extracted from <i>Mycobacterium bovis</i> BCG] Kekkaku. 1994 Sep;69(9):571-4. Japanese. | Y |
| | YOUN et al., Immunostimulatory DNA reverses established allergen-induced airway remodeling. J Immunol. 2004 Dec 15;173(12):7556-64. | |
| | Patent Interference No. 105,526. Order – Bd.R. 104. Conference Call. Paper 211. September 30, 2008. | |
| | Patent Interference No. 105,526. Memorandum Opinion and Order (Decision on Motions) December 1, 2008. | |
| | Patent Interference No. 105,526. Judgement on Preliminary Motions under 37 C.F.R. §41.127 December 1, 2008. | |
| | Patent Interference No. 105,526. Paper 217. Raz Notice of Filing of a Notice of Appeal (Appeal to the Court of Appeals for the Federal Circuit). January 27, 2009. | |
| | Patent Interference No. 105,526. Paper 218. Raz Notice of Withdrawal of Appeal. May 15, 2009. | |

EXAMINER:

/N. M. Minnifield/ (08/01/2010)

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/818,918, filed March 27, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 10/743,625	ATTY. DOCKET NO.: C1039.70073US00
FILING DATE: December 22, 2003	CONFIRMATION NO.: 9416
APPLICANT: Arthur M. Krieg et al.	
GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

Sheet 8 of 8

Patent Interference No. 105,674. Paper No. 1. Declaration under 37 C.F.R. §41.203(b) December 1, 2008.

Patent Interference No. 105,674. Paper No. 6 Raz Notice of Real Party in Interest. December 12, 2008.

Patent Interference No. 105,674. Paper No. 11 Krieg Designation of Real Party in Interest. December 15, 2008.

Patent Interference No. 105,674. Paper No. 15. Order - Bd.R. 104(c) Summary of December 23, 2008 Conference Call.

Patent Interference No. 105,674. Paper No. 19. Order-Bd.R. 104(c). Conference Call. January 16, 2009.

Patent Interference No. 105,674. Paper No. 21. Raz Observations (regarding evidence to support certain proposed motions. January 27, 2009.

Patent Interference No. 105,674. Paper No. 23. Raz Miscellaneous Motion 1 (to revive the Raz parent application). January 27, 2009.

Patent Interference No. 105,674. Paper No. 25. Order - Bd.R. 104(c) (Raz v. Krieg) Summary of Conference Call on February 4, 2009.

Patent Interference No. 105,674. Paper No. 29. Joint Submission Pursuant to Order Dated January 16, 2009. March 11, 2009.

Patent Interference No. 105,674. Paper No. 32. Raz Abandonment of Contest. May 15, 2009.

Patent Interference No. 105,674. Paper No. 33. Judgment -Bd.R.127. May 20, 2009.

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:

/N. M. Minnifield/ (08/01/2010)

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/818,918, filed March 27, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).